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LRP/Amyloid -Peptide Interaction
Mediates Differential Brain Efflux of A Isoforms
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et al., 2002), leading to increased A production (UleryLRP (low-density lipoprotein receptor-related protein)
et al., 2000). It may be involved in 2M-mediated slowis linked to Alzheimer’s disease (AD). Here, we report
reuptake of secreted A by neurons derived from trans-amyloid -peptide A40 binds to immobilized LRP
genic APP mice and in mouse fibroblasts with no degra-clusters II and IV with high affinity (Kd  0.6–1.2 nM)
dation of A (Qiu et al., 1999; Kang et al., 2000). Slowcompared to A42 and mutant A, and LRP-mediated
degradation of A via 2M in mouse fibroblasts and U97A brain capillary binding, endocytosis, and trans-
human glioma cells has also been suggested (Naritacytosis across the mouse blood-brain barrier are sub-
et al., 1997). ApoE3 may prevent A neurotoxicity bystantially reduced by the high  sheet content in A
forming complexes with A, and its protective effectand deletion of the receptor-associated protein gene.
possibly requires LRP (Jorda´n et al., 1998), althoughDespite low A production in the brain, transgenic
the role of other lipoprotein receptors, e.g., LDLR andmice expressing low LRP-clearance mutant A de-
megalin, cannot be ruled out.velop robust A cerebral accumulations much earlier
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along the brain capillary membranes clears A in vivotion and/or A-induced LRP loss at the BBB mediate
has been supported by brain efflux studies with exoge-brain accumulation of neurotoxic A.
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Figure 1. SPR Analysis of the Interaction be-
tween A and Recombinant LRP Fragments
(A) Differential binding of A40 and A42 to
LRP cluster II immobilized at a CM5 chip at
a density of 10 fmol/mm2. Incubation condi-
tions as in Experimental Procedures.
(B) Differential binding of A40, A42, and
mutant A (Dutch/Iowa40, DIA40) to immo-
bilized LRP cluster IV under conditions as
in (A).
(C) Kinetic parameters for the binding of dif-
ferent A species to LRP plotted against the
content of  sheets in A peptides deter-
mined by circular dichroism analysis. Apparent affinity constants Kd(app) were deferred from the ratios of koff(app)/kon(app) as described in Experimental
Procedures. Means  SEM (n  3–5); SEM  5% of the mean in (A) and (B). Kd(app) (mean  SD) values were determined from 6–9 different
concentrations of A and 3–5 independent measurements at each concentration. RAP, receptor-associated protein (500 nM); RU, reso-
nance units.
LRP in AD have been associated with A brain accumu- Figure 2A shows differential LRP-dependent binding
of A isoforms at the abluminal side of brain capillaries,lations (Kang et al., 1997, 2000; Shibata et al., 2000), but
i.e., A40  A42  Dutch/Iowa A40, and no bindingwhether A directly interferes with LRP’s internalization,
of the reverse 40-1 peptide, consistent with the SPRdegradation, and/or synthesis at the clearance site(s) in
findings (Figure 1). Binding of A was displaced by RAPbrain is not known.
and LRP-specific IgG (Figure 2A) and excess of unla-Here, we provide evidence for a direct LRP/A pro-
beled ligand (not shown). Figure 2B illustrates differen-tein-protein interaction and demonstrate that this inter-
tial LRP-mediated internalization of 125I-labeled A iso-action on brain capillaries regulates in an isoform-spe-
forms into brain endothelium, i.e., A40A42DIA40,cific manner binding of A to LRP followed by A
and inhibition (85%) with RAP and LRP-specific IgG.endocytosis and transcytosis across the BBB. We report
The half-time (t1/2) of LRP internalization in the presencethat LRP at the BBB favors clearance of A40 relative
of different A isoforms was similar between 26 andto a high  sheet content A42 and vasculotropic mutant
30 s (Figure 1C). During internalization, there was noA, while deletion of the RAP gene/depletion of LRP
significant degradation of A by brain endothelium as(Veinbergs et al., 2001), but not of the LDLR and VLDLR
indicated by negligible non-trichloracetic acid (TCA)-genes, precludes rapid A brain capillary clearance and
precipitable counts in brain capillary cell lysates (Figureefflux at the BBB. Transgenic mice producing low LRP-
1D) and in the medium (not shown). The short-term ki-clearance mutant A in the brain develop robust A
netic uptake studies at 37C confirmed a saturable LRP-accumulations compared to Tg-2576 wild-type A-over-
dependent clearance of A40 by brain capillaries withproducing mice (Hsiao et al., 1996), despite 20-fold
the Michaelis constant Km of 10  2 nM and 85%lower brain APP expression and 30-fold reduced A
inhibition of uptake by RAP and LRP-specific IgG (Figureneuronal production. Finally, we show Adoes not affect
2D). The kinetic inhibitory constants, Ki, confirmed thatLRP internalization or synthesis but promotes protea-
Dutch A40, wild-type A42, Dutch A42, and Dutch/some-dependent LRP degradation at pathological lev-
Iowa A40 exhibit 6-, 14-, 18-, and 22-fold lower affinitiesels consistent with low LRP activity in brain microvessels
for LRP-mediated brain capillary clearance than A40,in A-accumulating mice and in patients with AD and
respectively (Figure 2E).familial cerebrovascular -amyloidosis.
Next, we compared [125I]A clearance by brain mi-
crovessels derived from RAP null, LDLR null, VLDLR
Results null, and control mice. The Western blot analysis indi-
cated that LRP in brain capillaries of RAP null mice was
Figures 1A and 1B show high-affinity binding of mono- decreased by 75% compared to controls (Figure 3A),
meric A40 to immobilized LRP clusters II and IV with while VLDLR and LDLR levels were reduced by approxi-
Kd values of 0.57 012 and 1.24 0.01 nM, respectively, mately 40%. LRP-positive vascular profiles in different
determined by the surface plasmon resonance (SPR) brain regions in RAP null mice were reduced to 14%–
analysis. In contrast, A42 and vasculotropic mutant A 16% versus 60%–70% in controls, as indicated by dou-
(Dutch/Iowa A40 double mutant model peptide; Van ble staining for LRP and endothelial cell marker CD31
Nostrand et al., 2001) exhibit greatly reduced binding (Figures 3B and 3C). Deletion of the RAP gene resulted
affinity for LRP clusters II and IV by 6- and 9-fold and in about 80% reduction in brain capillary clearance of
28- and 12-fold, respectively, compared to A40. The A40, A42, and DIA40 (Figure 3D), while deletion of
Kd values for A42 binding to LRP II and IV clusters were the VLDLR and LDLR genes did not significantly affect
3.00  0.11 and 10.10  0.03 nM, respectively, and for A clearance (Figure 3E).
mutant A, 15.10  0.10 and 15.30  0.07 nM, respec- Figure 4A compares efflux across the BBB of 125I-
tively. Binding of A to LRP was abolished by RAP, an labeled A40 and mutant A (Dutch/Iowa A40) microin-
LRP antagonist (Figures 1A and 1B; Herz and Strickland, fused simultaneously with [14C]inulin (reference marker)
2001). Its affinity to immobilized LRP fragments was into brain ISF, as described (Shibata et al., 2000). In vivo
greatly reduced by the high content of  sheets (Fig- transcytosis rates of 125I-labeled A at the BBB were
obtained after correcting for the tracer’s passive diffu-ure 1C).
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Figure 2. LRP-Mediated A Binding, Inter-
nalization, and Clearance on Mouse Brain
Capillaries
(A) Binding of [125I]A ligands (2 nM) to the
abluminal brain capillary surface was deter-
mined at 4C for 30 min. RAP (500 nM); LRP,
LRP-specific IgG (Fab2, 60 g/ml); A40-1,
reverse A40 peptide.
(B) Internalization of A peptides at the ablu-
minal brain capillary surface. Capillaries were
incubated with [125I]A ligands (2 nM) at 4C
for 30 min and than at 37C for the indicated
times. The fraction of internalized ligand was
calculated as in the Experimental Procedures
and plotted against the internalization time.
RAP (500 nM); LRP (60 g/ml).
(C) The half-time (t1/2) of LRP endocytosis de-
termined with 2M* and different A ligands
from (B).
(D) Undetectable 125I non-TCA precipitable
counts (125I non-TCA) in lysed BEC during in-
ternalization of [125I]A ligands (2 nM).
(E) Rapid saturable A40 uptake by brain cap-
illaries determined at 37C within 1 min using [125I]A40 (1 nM) and increasing concentrations of unlabeled A (1–120 nM). RAP (1 M); LRP
and a nonimmune IgG, NI IgG (60 g/ml).
(F) Ki (inhibitory constant) for LRP-mediated brain capillary clearance of A isoforms plotted against A  sheet content. Ki values were
determined with [125I]A40 (2 nM) and 40 nM unlabeled A40, A42, and mutant A (Dutch40, DA40; Dutch42, DA42; Dutch/Iowa40, DIA40).
Means  SEM (n  3–5).
sion via the ISF bulk flow by subtracting the elimination in RAP null/severely depleted LRP mice (Figure 4D),
while deletion of the LDLR and VLDR genes did notrate of [14C]inulin, as explained in the Experimental Pro-
cedures. At concentrations comparable to physiological significantly affect A clearance at the BBB (Figure 4D).
Since LDLR and VLDLR do not contribute to rapid Alevels of soluble A in brain ISF (i.e., 1 nM) (Cirrito et
al., 2003), A40 was cleared rapidly across the BBB clearance in RAP null mice (Figures 3E and 4D) and
LRP on neurons in vivo does not mediate A clearancewithin a few seconds. In contrast, only 40% of mutant
Awas cleared across the BBB over a much longer time (Zerbinatti et al., 2004), one can speculate that increased
amount of amyloid in double crossed RAP null/APP over-period of 30 min. At higher concentrations, mutant A
was almost devoid of clearance at the BBB, while A40 expressing mice (Van Uden et al., 2002) could be related
to inefficient LRP-mediated A clearance across the BBB.still exhibited a substantial clearance. RAP and an anti-
LRP antibody, but not a nonimmune immunoglobulin G To validate our clearance hypothesis for endogenous
A, we compared A accumulation in transgenic Dutch/(NI IgG) (Figure 4A), almost abolished A elimination
across the BBB. Iowa (Tg-DI) mice expressing low levels of human APP
under control of Thy 1.2 neuronal promoter harboringA significant (p 	 0.05) crossinhibition of [125I]A40
efflux at the BBB by unlabeled A42 and mutant A and the Dutch (Levy et al., 1990) and Iowa (Grabowski et al.,
2001) vasculotropic mutations (Davis et al., 2004) versusa pronounced 95% inhibition of 125I-labeled A42 and
mutant A clearance by unlabeled wild-type A40 (Fig- Tg-2576 APP overexpressing mice (Hsiao et al., 1996).
Tg-DI mice produce mainly mutant A40 (Dutch/Iowa)ure 4B) indicated that all A peptides compete for the
same LRP-mediated efflux system to exit the brain, and (Figure 5C) that, compared to the wild-type A40, binds
to LRP with significantly lower affinity (Figures 2B andA40 exerts a significant retention effect on A42 and
mutant A in vivo. All A test ligands microinfused into 2C) and exhibits low LRP-clearance on brain capillaries
(Figures 2B and 3D) and across the BBB (Figures 4Abrain ISF in the presence of unlabeled A remained
97% in their monomeric forms (Shibata et al., 2000; and 4C). At 3, 6, and 12 months of age, APP levels
in the brain of Tg-DI mice versus Tg-2576 mice wereZlokovic et al., 2000), as confirmed by the HPLC (Figure
4B, insets) and SDS-PAGE analyses (not shown) of brain considerably lower by 24-fold (Figures 5A and 5B, left).
In fact, the Tg-DI mice express human APP at 	50%homogenates. During relatively short incubation time
and low nM levels of [125I]A ligand and the cold peptide, the levels of endogenous mouse APP, as reported in
three independent lines (Davis et al., 2004). Despite sub-[125I]A did not bind to unlabeled A, consistent with
reports suggesting significantly higher concentrations stantially lower levels of human APP (Figure 5B, left) and
30-fold lower neuronal production of A compared toof A, and longer times are required for A oligomeriza-
tion or aggregation (Dahlgren et al., 2002; Kayed et Tg-2576 mice (Figure 5B, right), the Tg-DI mice exhibited
earlier onset and more robust brain accumulations ofal., 2003).
The Ki values indicated that A42 and mutant A ex- A than Tg-2576 mice (Figure 5C), i.e., by 15- and 5-fold
higher for the 40 and 42 isoforms, respectively, at 6hibit 8- and 15-fold lower affinity for LRP-mediated efflux
at the BBB in vivo than A40, consistent with their high months of age.
Tg-DI mice developed early A plaque-like deposits sheet content (Figure 4C). There was 75% to 85%
inhibition of A40 and A42 rapid efflux across the BBB in the cortex and hippocampus at 3 months of age (Fig-
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Figure 3. Low LRP-Mediated A Clearance on Brain Microvessels in RAP Null Mice
(A) LRP, LDLR, and VLDLR brain capillary levels in wild-type and RAP null (RAP
/
) mice by Western blot analysis. LRP-85, LRP -chain-
specific IgG (5A6). Scanning densitometry of LRP, LDLR, and VLDLR bands relative to -actin in wild-type (control, open bar) and RAP
/

(closed bar) mice.
(B) Double immunostaining for LRP and CD31 (endothelial cell marker) in brain tissue sections in wild-type (control) and RAP null mice; scale
bar equals 50 m.
(C) LRP-positive vascular profiles in different brain regions in wild-type mice (open bars) and RAP null mice (closed bars).
(D) Brain capillary clearance of 125I-labeled A40, A42, and mutant A (Dutch/Iowa40, DIA40) in wild-type mice (open bars) and RAP null
mice (closed bars) studied at 1 nM peptides concentration. *p 	 0.01 RAP null compared to controls; LRP, LRP-specific N20 polyclonal
antibody (60 g/ml).
(E) Brain capillary clearance of [125I]A40 (1 nM) in LDLR null and VLDLR null mice. Means  SEM (n  3–5).
ure 5D, left), while the Tg-2576 mice (Hsiao et al., 1996; Figures 6A–6D indicate that A40, A42, and/or mu-
tant A (Dutch/Iowa A40) at lower concentrations (10Kawarabayashi et al., 2001) initially present A deposits
at 9 months of age (not shown). Similarly, the APP/ nM) do not alter LRP expression in primary human brain
endothelial cells (BEC). However, at levels 1 M overPS-1 knockin mice homozygous for both the humanized
APP and the PS-1 knockin mutation, which causes an longer periods of time (i.e., 48 hr), all A species down-
regulated LRP in BEC in a concentration-dependentincrease in the amount of A42, only develop A depos-
its at 6 months of age (Flood et al., 2002). Abundant manner, as demonstrated for LRP 85 kDa  subunit
(Figures 6A–6D) and 515 kDa  subunit (not shown). RAPA plaque-like diffuse deposits with significant micro-
vascular intracerebral association were found in Tg-DI and LRP-specific IgG, but not a control nonimmune IgG
(not shown), blocked A-induced LRP downregulation.mice at 12 months (Figure 5D, right). Plasma levels of
mutant A in Tg-DI mice were extremely low, i.e., 	25 A treatment did not reduce the expression of other cell
surface receptors in BEC, as, for example, the levelspM, consistent with the low clearance across the BBB
(Figure 4A). Double immunostaining for LRP and endo- of the receptor for advanced glycation end products
(RAGE) were increased (not shown) as reported (Deanethelial cell marker CD31 indicated substantial reduction
of LRP-positive vascular profiles in several brain regions et al., 2003) and the levels of transferrin receptor remain
unchanged (not shown). TUNEL and Hoechst stainingin Tg-DI and Tg-2576 mice at 4–6 months of age, i.e.,
only 5%–20% and 25%–30% of microvessels were posi- in BEC were negative, and the levels of lactic acid dehy-
drogenase in the medium did not increase from controltive for LRP, respectively, compared to 65%–75% of
LRP-positive vessels in age-matched littermate controls values (not shown).
A40, A42, and mutant A at 20M over 48 hr signifi-(Figure 5E). Significant LRP brain capillary reduction in
transgenic mice was confirmed by Western blot analysis cantly reduced (60%) the amount of internalized
[125I]2M* into human BEC (Figure 7A), consistent with(Figure 5F). The decrease in LRP vascular profiles at
12 months of age was also more pronounced in A- significantly reduced LRP levels (Figure 6D). However,
this treatment did not significantly alter the LRP endocy-accumulating transgenic mice than in controls (Figure 5G).
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was barely detectable in patients with Dutch-type cere-
brovascular -amyloidosis.
Discussion
A accumulation in the brain is a chief pathogenic event
(Hardy and Selkoe, 2002). Increased A42 levels lead
to formation of neurotoxic A oligomers, resulting in
progressive synaptic, neuritic, and neuronal dysfunction
(Walsh et al., 2002; Dahlgren et al., 2002; Kayed et al.,
2003; Gong et al., 2003). Missense mutations inside the
A sequence associate with vascular deposits in pa-
tients with the Dutch mutation (G to C at codon 693,
Glu to Gln at position 22; Levy et al., 1990) and Iowa
mutation (G to A at codon 694, Asp to Asn at position
23; Grabowski et al., 2001). How A accumulates in the
brain is unclear. Increased A production can explain a
small fraction of early onset AD familial cases bearing
inherited mutations in the APP gene flanking the A
coding region (i.e., Swedish mutation) or PS-1 or -2
genes. This leaves inefficient A clearance as a major
mechanism mediating A cerebral accumulation in late-
onset AD (Selkoe, 2001; Zlokovic and Frangione, 2003)
and familial forms of cerebrovascular -amyloidoses
(Ghiso and Frangione, 2002).
Figure 4. LRP-Mediated Transport of A across the Mouse BBB
Here, we report LRP/A direct interaction at the BBBIn Vivo
critically influences A brain accumulation by promoting(A) Efflux of mutant A (Dutch/Iowa40, DIA40; open points) versus
retention of high  sheet neurotoxic A42 and vasculo-wild-type A40 (solid points) across the BBB within 30 min of brain
tropic mutant A while clearing soluble A40 from brainISF [125I]A microinjections at 1–120 nM carrier concentration. RAP
(1 M); LRP, LRP-specific IgG (60 g/ml); NI IgG, nonimmune IgG ISF to blood. The SPR analysis (Figure 1) used as a first
(60 g/ml; closed square). *p 	 0.05 and **p 	 0.01 for DIA40 step to characterize A interaction with the LRP ligand
versus A40. binding domains (Herz and Strickland, 2001) revealed
(B) Efflux across the BBB of 125I-labeled A40, A42, and mutant A
that A40 binds to LRP with high affinity compared to(Dutch/Iowa40, DIA40) at 40 nM in the absence and presence of
A42 and mutant A. Consistent with the SPR findings,unlabeled A (120 nM). [125I]A monomers (HPLC analysis) in brain
we next showed that LRP-mediated A brain capillaryhomogenates 30 min after microinfusion of 125I/unlabeled Amixture
into brain ISF (insets above bars). binding and endocytosis in vitro and transcytosis across
(C) Ki values for LRP-mediated efflux at the BBB of A40, A42, the BBB in vivo in mice are substantially reduced by the
and mutant A (Dutch/Iowa40; DIA40) plotted against A  sheet high  sheet content in A (Figures 2–4) and deletion
content. Ki values were determined with [125I]A40 at 40 nM and of the RAP gene, but not the LDLR and VLDLR genesunlabeled A at 120 nM.
(Figures 3–4).(D) A40 and A42 efflux across the BBB in RAP null mice (RAP
/
;
In contrast to remarkable LRP-mediated A40 bindingclosed bars) versus wild-type mice (control, open bars), and A40
efflux in LDLR null and VLDLR null mice. Means  SEM (n  3–8). and endocytosis at the abluminal side of brain microves-
sels (Figures 2 and 3) and abluminal to luminal trans-
cytosis across the BBB in vivo (Figure 4), our earlier
study failed to detect significant receptor-mediatedtosis rate, and the t1/2 for LRP endocytosis in the pres-
ence of different A isoforms remained unchanged com- A40 basolateral to apical transport in cultured brain
endothelial monolayers (Mackic et al., 1998). It is possi-pared to controls, i.e., about 15 s (Figure 7B). On the
other hand, the pulse-chase studies revealed that A42 ble that the density of LRP receptors at the basolateral
membrane in the monolayer cultures (Mackic et al.,(20 M) decreases the half-life (t1/2) for LRP from 9.6 to
6.4 hr (Figures 7C and 7D). MG132, an inhibitor of the 1998) was much lower than at the abluminal membrane
of freshly isolated brain capillaries and at the BBB in vivoproteasome-dependent LRP degradation (Melman et
al., 2002), increased the t1/2 for LRP in control and (Figures 2–4), which could account for the loss of LRP-
dependent A40 basolateral to apical flux in monolayersA-treated cells (Figures 7E and 7F). Immunoblot analy-
sis with an anti-LRP C-terminal antibody that recognizes (Mackic et al., 1998) and may explain the discrepancies
between results obtained in the monolayer transportan immature 600 kDa form of LRP confirmed that the
levels of immature LRP are not affected by A treatment model versus present and previous study (Shibata et
al., 2000).(Figure 7G), suggesting no effect on LRP synthesis.
LRP-positive vascular profiles in human brain tissue The present data show that rapid interaction of A
with LRP does not require chaperone molecules. How-revealed greatly reduced LRP expression in patients
with AD and cerebrovascular -amyloidosis Dutch-type ever, this does not rule out the possibility that A may
also interact with LRP via chaperone molecules. Thus,compared to age-matched controls (Figures 8A and 8B).
The number of LRP-positive cerebral vessels dropped both direct and indirect interaction of A with LRP may
exist in parallel. For example, 2M can mediate via LRPfrom 45% in age-matched controls to 12% in AD and
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Figure 5. A Accumulation in Transgenic Mice Expressing Low LRP-Clearance Mutant A versus Wild-Type A
(A) Immunoblot analysis of human APP in the brain of transgenic Tg-DI mice expressing mutant APP harboring Dutch and Iowa mutations
versus Tg-2576 mice.
(B) APP levels in the brain of Tg-DI mice versus Tg-2576 mice at 6 months of age (left) and A production from isolated mouse neurons into
culture medium (right) determined by quantitative immunoblot analyses.
(C) Brain accumulation of low LRP-clearance mutant A40 and A42 (Dutch/Iowa, black bars) in Tg-DI mice versus wild-type A40 and A42
(gray bars) in Tg-2576 mice.
(D) Early deposits of mutant A (Dutch/Iowa) in the brain of Tg-DI mice at 3 months of age (scale bar equals 200 m), and abundant diffuse
deposits with significant intracerebral microvascular A deposits in Tg-DI mice at 12 months of age (scale bar equals 50 m) detected by
immunostaning for A.
(E) LRP-positive brain microvessels in Tg-DI mice (black bars), Tg-2576 mice (gray bars), and controls (open bars) at 4–6 months of age.
(F) Western blot analysis of LRP levels in mice in (E).
(G) LRP-positive microvessels in Tg-DI mice (black bars), Tg-2576 mice (gray bars), and controls (open bars) at 12 months of age. Mean 
SEM (n  4 mice). *p 	 0.001 and **p 	 0.01 in (B) and (C) for APP and A levels in Tg-DI mice compared to Tg-2576 mice.
slow A uptake into neurons isolated from transgenic (Figure 5; Hsiao et al., 1996; Kawarabayashi et al., 2001).
Significant intraparenchymal microvascular A associa-APP mice (Qiu et al., 1999) as well as into mouse fibro-
blasts (Kang et al., 2000). Degradation of A via 2M in tion points to brain’s blood vessels as a site of deficient
clearance in Tg-DI mice consistent with prominentU97 human glioblastoma cells and mouse fibroblasts
may also require LRP (Narita et al., 1997). cerebrovascular pathology in Dutch and Iowa patients
(Vinters and Farag, 2003). Increased fibrillogenicity ofDespite extremely low human APP expression/A
production, i.e., 25- to 30-fold lower than Tg-2576 mice, mutant Dutch/Iowa A (Van Nostrand et al., 2001) may
contribute to its decreased clearance from brain, butTg-DI mice (Davis et al., 2004) expressing low LRP-
clearance mutant Adevelop robust Abrain accumula- the presence of mainly nonfibrillar A parenchymal de-
posits in Tg-DI mice would argue against this possibility.tions much earlier than Tg-2576 A-overproducing mice
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Figure 6. LRP Downregulation in Human
Brain Endothelium by Excess A
(A–C) Western blot analysis of LRP  subunit
(LRP-85) in brain endothelium exposed for 48
hr to different concentrations of A40, A42,
and mutant A (Dutch/Iowa40; DIA40) from
1 nM to 20 M. RAP (1.25 M) and LRP,
LRP -chain-specific IgG F(ab)2 (25 g/ml)
were incubated 1 hr prior to the addition of
A peptides and then for 48 hr simultaneously
with different A peptides.
(D) Relative intensity of LRP bands in brain
endothelium exposed to different A pep-
tides was determined by scanning densitom-
etry and normalized for -actin. Mean SEM
(n 3–5 independent experiments); *p	 0.01
and **p 	 0.05 for the relative expression of
LRP levels in the presence of a given A con-
centration compared to the absence of A.
In addition to reduced LRP-mediated A efflux, an in- degradation by extracellular A. One can speculate that
A accumulations adjacent to brain vasculature maycreased formation of nonfibrillar A species might favor
A deposition in this model. downregulate LRP at the BBB in vivo consistent with
reduced brain capillary LRP levels in transgenic A-The present data show that A at pathological con-
centrations reduces LRP levels in brain endothelium by accumulating mice (Figures 5E–5G), AD, and patients
with the Dutch-type cerebrovascular -amyloidosis (Fig-accelerating proteasome-dependent LRP degradation
(Melman et al., 2002), while the receptor’s internalization ure 8) and reduced total brain LRP in AD (Kang et al.,
2000; Shibata et al., 2000).and synthesis are not affected (Figures 6 and 7). In con-
trast to LRP downregulation by simultaneous overex- In contrast to LRP, RAGE mediates a continuous influx
of circulating A into the brain and is overexpressed inpression of secreted ligands such as apoE, resulting in
retention and degradation of LRP in the endoplasmic brain vasculature in transgenic APP models and in AD
(Deane et al., 2003). Thus, an imbalance between LRP-reticulum (ER) (Willnow et al., 1996; Herz and Mars-
chang, 2003), binding of internalized A to immature mediated and RAGE-mediated A transport at the BBB
would create a positive feedback amplification mecha-LRP in the ER compartment is not implicated in LRP
Figure 7. High A Levels Reduce LRP’s Half-
Life in Human Brain Endothelium
(A) Internalization of [125I]2M* by human BEC
treated with 20M of A40, A42, and mutant
A (DIA40) for 48 hr.
(B) The half-life (t1/2) for rapid LRP endocytosis
in human BEC in (A) determined with
[125I]2M*.
(C) Cells were labeled by [35S]methionine for
1 hr and chased for the indicated times. Auto-
radiograph of 35S-methionine-labeled LRP
immunoprecipitated with LRP 515 kDa  sub-
unit-specific IgG in the presence and ab-
sence of A42 (20 M).
(D) Graph of LRP levels from three indepen-
dent experiments as in (A). *p 	 0.05 and
**p 	 0.01 in the presence of A compared
to the corresponding control value.
(E) Effects of the proteasomal inhibitor
MG132 (20 M) on LRP levels in the presence
and absence of A42 (20 M) determined at
8 hr. Autoradiograph of 35S-methionine-labeled
LRP immunoprecipitated with LRP 515 kDa
 subunit-specific IgG. Graph of LRP levels
from three independent experiments as in (C).
(F) Western blot analysis for immature 600
kDa LRP (LRP-600) in the presence of A40,
A42, or mutant A (Dutch/Iowa40, DIA40)
at 20 M within 48 hr, as demonstrated with
LRP-specific IgG directed to the C-terminal
region of LRP (5A6). RAP was used at 1.2 M.
Mean  SEM (n  3) in (B) and (D).
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Figure 8. LRP Expression in Brain Microves-
sels in Alzheimer’s and Dutch Patients
(A) Immunostaining for Von Willebrand factor
(vWF, endothelial cell marker) and LRP in cor-
tical sections (Brodman area 10) in age-
matched controls and AD and Dutch patients
with cerebrovasular -amyloidosis. Scale bar
equals 50 m.
(B) LRP-positive vessels in controls, AD, and
Dutch patients. Mean  SEM (n  4 cases/
group).
Secondary Structure Analysisnism for A accumulation in AD and related familial
Secondary structure of peptides was analyzed by circular dichroismcerebrovascular disorders. The present findings raise a
(Zlokovic et al., 1996; Golabek et al., 1996). Briefly, 20–25 g ofpossibility that efficacy of A lowering therapies with
hexafluoroisopropanol-treated seedless peptide was dissolved in
peripheral A sequestering agents (DeMattos et al., 980l of 10 mM phosphate buffer (pH 7.4) and centrifuged to remove
2002a; Deane et al., 2003; Matsuoka et al., 2003) may precipitated/undissolved material. The CD spectrum was recorded
within 24 hr using a 1 mm path length cell on an Aviv 202 CDdepend at least in part on preserved LRP activity at
spectropolarimeter (Proterion, Piscataway, NJ). Results are ex-the BBB. Whether therapeutic modifications of A/LRP
pressed as molar ellipticity and the percentage of  helix,  sheet,interaction at the BBB will have a major impact on con-
-turn, and random coil determined.trolling dementia remains to be seen in the future.
Radioiodination of AExperimental Procedures
Radioiodination of A was carried out by mild “lactoperoxidase”
method (Thorell and Johansson, 1971). Typically, 10 g of A wasReagents
labeled for 18 min at room temperature with 2 mCi of [125I]Na. AfterWild-type and mutant A (Dutch40, Dutch42, Dutch/Iowa40) pep-
radiolabeling, the preparations were subjected to reverse-phasetides were synthesized by solid-phase F-moc (9-fluorenylmethoxy-
HPLC separation using a Vydac C4 column and a 30 min linearcarbonyl) amino acid chemistry, purified by reverse phase-HPLC,
gradient of 25% to 40% acetonitrile in 0.059% trifluoroacetic acidand structurally characterized, as described (Burdick et al., 1992;
to separate the monoiodinated nonoxidized form of A (which isVan Nostrand et al., 2001). Recombinant LRP fragments encom-
the tracer we are using) from diiodinated A, nonlabeled nonoxi-passing clusters II and IV were produced using stable transfected
dized A, and oxidized A species, as we reported (Deane et al.,baby hamster kidney cell lines (Westein et al., 2002). We used human
2003). The content of material in the peaks eluted from HPLC wasrecombinant RAP (EMD Biosciences, Inc., San Diego, CA), poly-
determined by MALDI-TOF mass spectrometry to ensure the purityclonal goat anti-human LRP N20 antibody, which crossreacts with
of the radiolabeled species. For MALDI-TOF mass spectrometry,mouse LRP (1:200, Santa Cruz Biotech. Inc., Santa Cruz, CA), mono-
A peptides were labeled under identical conditions using [127I]Naclonal mouse antibody against C-terminal domain of human LRP
instead of the radioactive nuclide. The specific activities were in the-chain, which crossreacts with mouse LRP (5A6, 1:350, 5 g/ml;
range of 45 to 65 Ci/g of peptide. For brain capillary uptakeEMD), monoclonal mouse antibody against human LRP  chain
studies and animal clearance studies, we used in most experiments(8G1,1:240, 5 g/ml; EMD), monoclonal mouse antibody P2-1 spe-
the preparations within 24 hr of labeling that were 99% TCA-cific for human APP (1:1000, 1 mg/ml), 22C11, which recognizes
precipitable. If used within 72 hr of labeling, the radiolabeled pep-mouse and human APP (1:100, 0.5 mg/ml; Chemicon International,
tides were stabilized in ethanol as a quenching agent. The HPLC/Temecula, CA), 66.1 to residues 1–8 of human A (1:1000, 1 mg/ml)
SDS-PAGE analysis was used to confirm the monomeric state of(Deane et al., 2003), rat anti-mouse CD31 antibody (1:200, BD Phar-
infused radiolabeled A.migen, Lexington, KY), polyclonal rabbit antibody to human von
Willebrand Factor, vWF (1:200, DAKO, Carpinteria, CA), RAGE-spe-
cific IgG (1:500, 1 mg/ml) (Deane et al., 2003), goat anti-human Brain Capillary Binding, Endocytosis, and Uptake of [125I]A
Brain capillaries from wild-type, RAP null, LDLR null, and VLDLRVLDLR (1:50, 200g/ml, Santa Cruz), and monoclonal mouse human
LDLR-specific IgG C7 (1:50, 200 g/ml, Research Diagnostics, Flan- null mice were isolated using a modified procedure, as we described
(Wu et al., 2003).ders, NJ).
First, we determined 125I-labeled A40, A42, Dutch/Iowa A40,
and reverse 40-1 A binding to endogenous LRP at the abluminalSurface Plasmon Resonance Analysis
LRP clusters II and IV immobilized at CM5 chips at a density of side of brain capillaries. Capillaries were incubated in 0.6 ml Eppen-
dorf tubes in the assay buffer (mock CSF containing 1 mM sodium10–20 fmol/mm2 and incubated with A40, A42, and mutant A
(Dutch/Iowa40) (0–50 nM) in 150 mM NaCl, 0.005% (v/v) Tween, and perchlorate to prevent free iodide binding/uptake) with 2 nM [125I]A
ligand at 4C for 30 min in the absence and presence of RAP (50025 mM HEPES (pH 7.4) at a flow rate of 5 l/min for 2 min at 25C,
as described (Westein et al., 2002). RAP was used at 500 nM. The nM), LRP-specific IgG (Fab2), and unlabeled A (500 nM). After 30
min, incubation buffer containing unbound ligand was removed anddata were analyzed to calculate apparent association rate constant
kon(app) and apparent dissociation rate constant koff(app) using a single- capillaries washed, lysed in low SDS lysis buffer, and counted.
Second, we determined internalization of 125I-labeled A40, A42,site binding model (Westein et al., 2002). Apparent affinity constant
Kd(app) was inferred from the ratio koff(app)/kon(app). Data are based on and Dutch/Iowa A40 at the abluminal surface of brain capillaries
and the rate of LRP endocytosis in the presence of each isoform.3–5 measurements using 6–9 different concentrations for each mea-
surement and presented as the average (SEM). Analysis was per- Capillaries were incubated in 0.6 ml Eppendorf tubes in cold assay
buffer with 2 nM [125I]A ligand at 4C for 30 min in the absence andformed using Biacore X biosensor system (Uppsala, Sweden) and
BIA evaluation 3.0 software (Biocore, Sweden). presence of RAP (500 nM), LRP-specific IgG (Fab2), and unlabeled
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A (500 nM), as above. After 30 min, unbound ligand was removed Calculations
[125I]A brain capillary uptake was corrected for the distribution ofby washing capillaries with cold assay buffer. Ice-cold stop/strip
solution (0.2 M acetic acid [pH 2.6], 0.1 M NaCl) was added to one [14C]inulin (extracellular space marker) and determined as the tissue
to medium ratio: c.p.m. for TCA-precipitable 125I-radioactivity (mgEppendorf tube that was kept on ice. The remaining Eppendorf
tubes were placed in a 37C water bath, and the assay buffer at 37C capillary protein)/c.p.m. for TCA-precipitable 125I-radioactivity (ml
medium). All calculations of clearance parameters were as reportedwas added quickly to capillaries to initiate ligand internalization. At
predetermined times at 30 s and 1, 2, and 5 min, Eppendorf tubes (Shibata et al., 2000). Briefly, the percentage of radioactivity re-
maining in the brain after microinjection was determined as % recov-were quickly placed on ice and incubated for 12 min with the ice-
cold stop/strip solution (0.2 M acetic acid [pH 2.6], 0.1 M NaCl) to ery in brain  100  (Nb/Ni), where Nb is the radioactivity remaining
in the brain at the end of the experiment and Ni is the radioactivityremove ligand from the capillary abluminal cell surface. Capillaries
were solubilized with low SDS lysis buffer and counted. The sum injected into the brain ISF, i.e., the d.p.m. for [14C]inulin and the c.p.m.
for TCA-precipitable [125I]radioactivity (intact A). The percentage ofof internalized ligand plus the ligand associated with the abluminal
capillary cell surface represented the amount of ligand available for A cleared through the BBB was calculated as [(1 
 Nb(A)/Ni(A)) 

(1 
 Nb(inulin)/Ni(inulin))]  100, using a standard time of 30 min. Effluxinternalization. The fraction of ligand internalized at each time point
was plotted, and the half-time for internalization (t1/2) was calculated, of A from brain ISF via transport across the BBB at different con-
centrations of peptides, Jout, was calculated as [(1 
 Nb(A)/Ni(A)) 
as described (Li et al., 2001).
[125I]A ligand degradation was determined in brain capillary endo- (1 
 Nb(inulin)/Ni(inulin))]/T  CA, where CA is A concentration in the
infusate. The half-saturation concentration for A elimination viathelial cell lysates and in the incubation medium at the end of inter-
nalization studies using the TCA precipitation assay, as reported BBB transport, Km, was calculated from JoutClmax/(KmCA), where
Clmax (pmol/s/l ISF) represents the maximal efflux capacity for the(Deane et al., 2003).
To determine kinetics of [125I]A brain capillary unidirectional up- saturable A efflux across the BBB corrected for the rate of ISF
flow, as we reported (Shibata et al., 2000). The Km value for A40take, capillaries were incubated with 125I-labeled A40, A42, and
mutant A (Dutch/Iowa40) at 37C for 1 min. Self- and crossinhibition uptake by isolated brain capillaries was calculated using Michaelis-
Menten analysis. The inhibitory constants, Ki, were calculated fromstudies were performed with unlabeled A40 from 1 to 120 nM and
unlabeled A42 and mutant A (Dutch40, Dutch42, Dutch/Iowa40) the velocity ratios (Zlokovic et al., 1996) as Ki  (Ji  Km  Ci)/(Jout 

Ji)(Km  CA40), where Ci and CA40 were the inhibitory concentrationsat 40 nM, RAP (500 nM), and LRP-specific polyclonal N20 antibody
(60 g/ml). of test A peptide and A40 in the infusate in vivo or incubation
medium in vitro. Kinetic constants were obtained by a nonlinear
regression curve fitting (Prism 3.0).Brain Clearance Studies
Studies were performed according to the National Institutes of
Health guidelines using an approved institutional protocol. CNS Transgenic Mice
clearance of 125I-labeled A ligands was determined simultaneously We used Tg-2576 mice in a C57Bl6/SJL background (Hsiao et al.,
with [14C]inulin (reference marker) in male C57Bl/6, RAP null, LDLR 1996) and Tg-DI (Dutch/Iowa) mice in C57Bl6 background (Davis et
null, and VLDLR null mice 8–10 weeks old, using a procedure as al., 2004). Human APP (770 isoform) cDNA harboring the Swedish
described (Shibata et al., 2000). Briefly, a stainless steel guide can- (KM670/671NL), Dutch (E693Q), and Iowa (D694N) mutations was
nula was implanted stereotaxically into the right caudate-putamen subcloned between exons II and IV of a Thy-1.2 expression cassette
of anesthetized mice (0.5 mg/kg ketamine and 5 mg/kg xylazine (gift from Dr. F. LaFerla, UC Irvine, Irvine, CA). The 9 kb transgene
i.p.). Coordinates for tip of the cannula were 0.9 mm anterior and was liberated by NotI/PvuI digestion, purified, and microinjected
1.9 mm lateral to the bregma and 2.9 mm below the surface of into pronuclei of C57BL/6 single cell embryos at the Stony Brook
the brain. Animals were allowed to recover after surgery prior to Transgenic Mouse Facility. Founder transgenic mice were identified
radiotracer studies. The experiments were performed before sub- by Southern blot analysis of tail DNA. Transgenic offspring were
stantial chronic processes occurred, as assessed by histological determined by PCR analysis of tail DNA using the following primers
analysis of tissue, i.e., negative staining for astrocytes (glial fibrillar for human APP: 5-CCTGATTGATACCAAGGAAGGCATCCTG-3:5-
acidic protein) and activated microglia (anti-phosphotyrosine), but GTCATCATCGGCTTCTTCTTCTTCCACC-3 (generating 500 base
allowing time for BBB repair to large molecules (Zlokovic et al., pair product). RAP null, VLDLR null, and LDLR null mice were pur-
2000), typically 4–6 hr after the cannula insertion, as reported (Cirrito chased from Jackson Laboratories (Bar Harbor, ME).
et al., 2003). Tracer fluid (0.5 l) containing [125I]A and [14C]inulin
was injected into brain ISF over 5 min via an ultra micropump with a
Quantification of A
micro4-controller (World Precision Instruments, Sarasota, FL). When
Soluble and insoluble pools of A were determined by ELISA of
the effects of different unlabeled molecular reagents are tested,
carbonate extracted forebrain tissue and of guanidine lysates of the
these were injected simultaneously with radiolabled ligands. For
insoluble pellets resulting from the carbonate extracted brain tissue,
self-inhibition studies, the uptake of 125I-labeled A40 and mutant
respectively (DeMattos et al., 2002b). Levels of total A were com-A (Dutch/Iowa40) was studied over a range of carrier concentra-
pared between Tg-2576 and Tg-DI mice.tions from 0.5 to 120 nM. For crossinhibition studies, efflux of
125I-labled test peptides was studied at a carrier concentration of
Histological Analysis40 nM and the inhibitory concentration of unlabeled A peptides at
For neuropathological analysis on mouse brain tissue in Tg-2576120 nM. Brain and blood were sampled 30 min after tracer injection
and Tg-DI mice, tissue sections were cut from mouse brain hemi-and prepared for radioactivity analysis by TCA, HPLC, and SDS-
spheres in the sagittal plane either at 5 m (paraffin embedded fixedPAGE/immunoprecipitation analysis to determine the molecular
tissue) or 14 m (fresh frozen tissue). A immunoreactive depositsforms of test tracers, as described (Zlokovic et al., 1996; Shibata et
were identified with human-specific monoclonal mouse antibodyal., 2000; Deane et al., 2003). Gamma counting was performed using
66.1 to A (Deane et al., 2003). For LRP staining on brain microves-Wallac Vizard Gamma Counter (Perkin Elmer, Meriden, CT) and
sels in RAP null, Tg-2576, Tg-DI, and wild-type mice, we used 14 m-counting using Tri-carb 2100 Liquid Scintillation Counter (Perkin
frozen acetone fixed tissue sections and double imunostaining forElmer, CT). Previous studies with 125I-labeled A demonstrated an
LRP and CD31 (endothelial marker). LRP-specific IgG (5A6) wasexcellent correlation between TCA and HPLC methods. The in-
used as a primary antibody. Biotinylated anti-mouse IgG was usedtactness of 125I-labeled A40, A42, and mutant A (Dutch/Iowa40)
as a secondary antibody and was detected with fluorescein strep-injected into the brain ISF was 99% by TCA/HPLC analysis. The
tavidin (1:1000, Vector Laboratories, Inc., Burlingame, CA). M.O.MA standards eluted between 29.1 and 31.2 min for different A
kit (Vector) was used to block endogenous IgG, as described (Satapeptides. For SDS-PAGE analysis, TCA-precipitated samples were
et al., 2002). For CD31 staining, mouse CD31-specific IgG was usedresuspended in 1% SDS, vortexed, and incubated at 55C for 5 min,
as a primary antibody and Alexa Fluor 594 donkey anti-rat IgG (1:500,then neutralized, boiled for 3 min, homogenized, and analyzed by
Molecular Probes, Eugene, OR) as a secondary antibody. For immu-electrophoresis in 10% Tris-tricine gels followed by fluorography.
nocytochemical analysis of LRP on brain microvessels in tissue fromMethodological details were as we reported (Zlokovic et al., 1996;
Shibata et al., 2000; Deane et al., 2003). AD patients, patients with cerebrovascular -amyloidosis Dutch-
Neuron
342
type, and age-matched controls, we used cryostat sections (10 m) References
of frontal cortex (Brodmann area 9/10) that were air dried. LRP was
detected with 8G1 human LRP-specific IgG as a primary antibody Bu, G. (2001). The roles of receptor-associated protein (RAP) as a
molecular chaperone for members of the LDL receptor family. Int.and rhodamine red goat anti-mouse IgG (1:150, Molecular Probes)
as a secondary antibody. The anti-vWF (endothelial marker) primary Rev. Cytol. 209, 79–116.
antibody was detected with fluorescein goat anti-rabbit IgG (1:150, Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M.,
Molecular Probes). Image analysis was performed using Olympus Henscehn, A., Yates, J., Cotman, C., and Glabe, C. (1992). Assembly
AX70 microscope equipped with the SPOT digital camera. Ten ran- and aggregation properties of synthetic Alzheimer’s A4/ amyloid
domly selected fields in each region from ten sections spanning the peptide analogs. J. Biol. Chem. 267, 546–554.
entire hemisphere from 4 mice/group or from Brodman A9/10 areas Cheng, T., Liu, D., Griffin, J.H., Fernandez, J.A., Castellino, F., Rosen,
in humans was performed. E.D., Fukudome, K., and Zlokovic, B.V. (2003). Activated protein C
blocks p53-mediated apoptosis in ischemic human brain endothe-
Human Brain Endothelial Cells lium and is neuroprotective. Nat. Med. 9, 338–342.
Human BEC were isolated from rapid autopsies of neurologically
Cirrito, J.R., May, P.C., O’Dell, M.A., Taylor, J.W., Parsadanian, M.,normal young individuals after trauma. BECs were characterized
Cramer, J.W., Audia, J.E., Nissen, J.S., Bales, K.R., Paul, S.M., et al.and cultured as we described (Cheng et al., 2003) and incubated
(2003). In vivo assessment of brain interstitial fluid with microdialysiswith different A isoforms at concentrations ranging from 1 nM to
reveals plaque-associated changes in amyloid- metabolism and20 M within 48 hr. Cells were lysed and equal amounts of proteins
half-life. J. Neurosci. 23, 8844–53.electrophoresed (10 g/ml) on 10% SDS-polyacrillamide gel, trans-
Dahlgren, K.N., Manelli, A.M., Stine, W.B., Baker, L.K., Krafft, G.A.,ferred onto nitrocellulose membrane, and probed with 5A6 (-chain)
and LaDu, M.J. (2002). Oligomeric and fibrillar species of amyloid-or 8G1 ( chain) human LRP-specific IgGs, RAGE-specific IgG
peptides differentially affect neuronal viability. J. Biol. Chem. 277,(Deane et al., 2003), or transferrin-specific IgG. The relative density
32046–32053.of each protein was determined by scanning densitometry using
-actin as an internal control. Davis, J., Xu, F., Deane, R., Romanov, G., Prevetti, M.L., Zeigler, K.,
Zlokovic, B.V., and Van Nostrand, W. (2004). Early-onset and robustLRP endocytosis rates were studied with [125I]2M*, an LRP-spe-
cific ligand. BEC were incubated with 20M A40, A42, and Dutch/ cerebral microvascular accumulation of amyloid -protein in trans-
genic mice expressing low levels of a vasculotropic Dutch/IowaIowa A40 at 37C for 48 hr in 12-well plates and then switched to
A-free medium containing 5 mM CaCl2 and 5 nM [125I]2M* at 4C mutant form of amyloid -protein precursor. J. Biol. Chem. 279,
20296–20306.for 30 min followed by incubations with 2M*-free medium at 37C
to initiate internalization, as reported (Li et al., 2001). Deane, R., Du Yan, S., Submamaryan, R.K., LaRue, B., Jovanovic,
S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003).
Metabolic Labeling RAGE mediates amyloid- transport across the blood-brain barrier
Human BEC (4  105) were pulsed for 1 hr at 37C with 400 Ci of and accumulation in brain. Nat. Med. 9, 907–913.
[35S]methionine (1000 Ci/mmol; Perkin Elmer Life Sci. Inc., Boston, DeMattos, R.B., Bales, K.R., Cummins, D.J., Paul, S.M., and Holtz-
MA) in methionine-free Dulbecco modified Eagle medium (GIBCO- man, D.M. (2002a). Brain to plasma amyloid-A efflux: a measure
BRL, New York, NY), as described (Guene´tte et al., 2002). Cells were of brain amyloid burden in a mouse model of Alzheimer’s disease.
chased at indicated times within 48 hr. Cell lysates were immuno- Science 295, 2264–2267.
precipitated with LRP-515 kDa  chain specific IgG (8G1) on
DeMattos, R.B., O’Dell, M.A., Parsadanian, M., Taylor, J.W., Har-SDS-PAGE. The intensity of signal was quantified in pixels using
mony, J.A., Bales, K.R., Paul, S.M., Aronow, B.J., and Holtzman,Storm 860 Phosphoimager (Amersham Biosciences Corp., Piscata-
D.M. (2002b). Clusterin promotes amyloid plaque formation and isway, NJ).
critical for neuritic toxicity in a mouse model of Alzheimer’s disease.
Proc. Natl. Acad. Sci. USA 99, 10843–10849.
Neuronal Cultures and A Production
Flood, D.G., Reaume, A.G., Dorfman, K.S., Lin, Y.-G., Lang, D.M.,Primary mouse neuronal cultures were prepared as we described
Trusko, S.P., Savage, M.J., Annaert, W.G., De Strooper, B., Siman,(Guo et al., 2004). Briefly, cerebral cortices were dissected from
R., and Scott, R.W. (2002). FAD mutant PS-1 gene-targeted mice:fetal heterozygous Tg-DI mice (Davis et al., 2004) and Tg-2576 mice
increased A42 and A deposition without APP overproduction.(Hsiao et al., 1996) at 16 days of gestation, treated with trypsin for
Neurobiol. Aging 23, 335–348.10 min at 37C, and dissociated with trituration. Cell suspensions
Ghiso, J., and Francione, B. (2002). Amyloidosis and Alzheimer’swere plated at 5  105 cells per well on 12-well plates in serum-free
disease. Adv. Drug Deliv. Rev. 54, 1539–1551.Neurobasal medium plus B27 supplement (GIBCO-BRL, Rockville,
MA). The absence of astrocytes was confirmed by the lack of glial Golabek, A.A., Soto, C., Vogel, T., and Wisniewski, T. (1996). The
fibrillar acidic protein. Cultures were maintained in a humidified 5% interaction between apolipoprotein E and Alzheimer’s amyloid beta-
CO2 incubator at 37C for 5 days and the levels of A in the culture peptide is dependent on beta-peptide conformation. J. Biol. Chem.
medium determined by a quantitative immunoblot analysis using 271, 10602–10606.
4G8 antibody (1:1000, 1 g/ml, Signet, Dedham, MA), similar as Grabowski, T.J., Cho, H.S., Vonsattel, J.P.G., Rebeck, G.W., and
described (Qiu et al., 1999). Greenberg, S.M. (2001). Novel amyloid precursor protein mutation
in an Iowa family with dementia and severe cerebral amyloid angio-
Statistical Analysis pathy. Ann. Neurol. 49, 697–705.
Data were analyzed by multifactorial analysis of variance, Student’s
Gong, Y., Chang, L., Viola, K.L., Lacor, P.N., Lambert, M.P., Finch,
t test, and Dunnett’s t test.
C.E., and Krafft, G.A. (2003). Alzheimer’s disease-affected brain:
presence of oligomeric A ligands (ADDLs) suggests a molecular
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